Showing results (181-190 of 258) with videos related to

Sort By:
Pageof 26
Oncotarget|November 20, 2019
Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancyTsung-I Hsu, Ying-Jung Chen, Chia-Yang Hung, et al.
Oncotarget|April 25, 2015
A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancyTsung-I Hsu, Ying-Jung Chen, Chia-Yang Hung, et al.
The Journal of Molecular Diagnostics : JMD|October 13, 2018
Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer AssessmentFang Wei, Charles M Strom, Jordan Cheng, et al.
International Journal of Cancer|January 3, 2014
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitorsYa-Ping Chen, Hui-Ju Lin, Jiann-Shiuh Chen, et al.
Scientific Reports|March 9, 2023
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsChang-Yao Chu, Chien-Yu Lin, Chien-Chung Lin, et al.
Scientific Reports|June 22, 2017
Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathwaysWen-Pin Su, Yen-Chih Ho, Cheng-Kuei Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic CholangiocarcinomaShubham Pant, Joon Oh Park, Wu-Chou Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.
Investigational New Drugs|June 29, 2016
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio Scagliotti, Jin Hyoung Kang, David Smith, et al.
Pageof 26